Patent application number | Description | Published |
20080312194 | Methods and compositions for normalizing meibomian gland secretions - The present invention provides non-aqueous compositions for normalizing meibomian gland secretions, and methods of use thereof. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of dry eye disease. | 12-18-2008 |
20090010850 | Formulations and methods for treating dry eye - The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. | 01-08-2009 |
20100130580 | Formulations and Methods for Treating Dry Eye - The present invention provides compositions comprising a low dose amount of an ophthalmic NSAID for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye and safe for chronic use. | 05-27-2010 |
20100240624 | Ophthalmic Formulations of Ketotifen and Methods of Use - The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of such treatment by topical application of the ketotifen formulations of the invention to the eye of a subject in need thereof. | 09-23-2010 |
20100240625 | Ophthalmic Formulations of Cetirizine and Methods of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 09-23-2010 |
20100311688 | OPHTHALMIC FORMULATIONS, METHODS OF MANUFACTURE, AND METHODS OF USING SAME - The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. Methods of manufacture are also provided. | 12-09-2010 |
20110105450 | OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE - The present invention provides ophthalmic formulations of fluticasone that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic conjunctivitis in a subject in need of such treatment by topical application of the fluticasone formulations of the invention directly to the eye. | 05-05-2011 |
20110257136 | Ophthalmic Formulations Of Cetirizine And Methods Of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis rhinitis, and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 10-20-2011 |
20120093876 | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions - The present invention provides process for producing non-aqueous compositions for normalizing meibomian gland secretions. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of dry eye disease. | 04-19-2012 |
20130252971 | Ophthalmic Formulations of Cetirizine and Methods of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 09-26-2013 |
20140045803 | Ophthalmic Formulations Of Cetirizine And Methods Of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis rhinitis, and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 02-13-2014 |
20140161903 | Compositions for the Treatment and Prevention of Eyelid Swelling - The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof. | 06-12-2014 |
20140343041 | Topical Ophthalmic Formulations for the Treatment and Prevention of Migraine Headache - The present invention provides topical ophthalmic formulations comprising a combination of one or more antihistamine agents and optionally one or more vasculature modifying agents such as a β adrenergic receptor antagonist. Also provided are methods of using the formulations of the invention for treating and/or preventing symptoms associated with migraine headache, and for reducing the frequency, severity and duration of migraine attacks. | 11-20-2014 |